お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
979349

乾性(萎縮性)黄斑変性症:世界の臨床試験レビュー(2020年下半期)

Dry (Atrophic) Macular Degeneration Disease - Global Clinical Trials Review, H2, 2020

出版日: | 発行: GlobalData | ページ情報: 英文 100 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=107.25円
乾性(萎縮性)黄斑変性症:世界の臨床試験レビュー(2020年下半期)
出版日: 2020年12月16日
発行: GlobalData
ページ情報: 英文 100 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、世界の乾性(萎縮性)黄斑変性症に関する臨床研究の最新動向について分析し、疾患・治療法の概要や、主要先進国・新興国 (G7/E7諸国) における治験の状況、地域別・フェーズ別 (相別)・段階別の進行状況、有望なスポンサー (治験依頼者)、各企業・研究機関での研究の進行状況、有望な薬剤の比較といった情報を盛り込んでいます。

目次

目次

表一覧

図一覧

  • レポートガイダンス
  • 調査範囲
  • 臨床試験:地域別
  • 臨床試験件数と平均登録数:国別
  • アジア太平洋地域の主要5カ国における臨床試験件数
  • 欧州の主要5カ国における臨床試験件数
  • 北米の主要5カ国における臨床試験件数
  • 中東・アフリカの主要5カ国における臨床試験件数
  • 中南米の主要5カ国における臨床試験件数
  • G7諸国別臨床試験件数:眼科の臨床試験に対する乾性(萎縮性)黄斑変性症の割合
  • G7諸国における臨床試験件数:フェーズ(相)別
  • G7諸国における臨床試験件数:治験状況別
  • E7諸国別臨床試験件数:眼科の臨床試験に対する乾性(萎縮性)黄斑変性症の割合
  • E7諸国における臨床試験件数:フェーズ(相)別
  • E7諸国における臨床試験件数:治験状況別
  • 臨床試験件数:フェーズ(相)別
  • 進行中の試験件数:フェーズ(相)別
  • 臨床試験件数:治験状況別
  • 臨床試験件数:エンドポイントステータス別
  • 一定期間にわたって募集された被験者
  • スポンサータイプ別臨床試験件数
  • 有望なスポンサー
  • 乾性(萎縮性)黄斑変性症治療薬の臨床試験に参加している主要企業
  • 有望な薬剤
  • 臨床試験専門家のスナップショット

付録

  • 略語
  • 定義
  • 調査方法
  • 2次調査
  • GlobalDataについて
  • お問い合わせ
  • 情報源
図表

List of Tables

List of Tables

  • Dry (Atrophic) Macular Degeneration Therapeutics, Global, Clinical Trials by Region, 2020*
  • Dry (Atrophic) Macular Degeneration Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2020*
  • Dry (Atrophic) Macular Degeneration Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2020*
  • Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2020*
  • Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Europe, Top Five Countries, 2020*
  • Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, North America, Top Countries, 2020*
  • Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2020*
  • Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Central and South America, Top Countries, 2020*
  • Proportion of Dry (Atrophic) Macular Degeneration to Ophthalmology Clinical Trials, G7 Countries (%), 2020*
  • Dry (Atrophic) Macular Degeneration Therapeutics, G7 Countries, Clinical Trials by Phase, 2020*
  • Dry (Atrophic) Macular Degeneration Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2020*
  • Proportion of Dry (Atrophic) Macular Degeneration to Ophthalmology Clinical Trials, E7 Countries (%), 2020*
  • Dry (Atrophic) Macular Degeneration Therapeutics, E7 Countries, Clinical Trials by Phase, 2020*
  • Dry (Atrophic) Macular Degeneration Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2020*
  • Dry (Atrophic) Macular Degeneration Therapeutics, Global, Clinical Trials by Phase, 2020*
  • Dry (Atrophic) Macular Degeneration Therapeutics, Global, Clinical Trials In Progress by Phase 2020*
  • Dry (Atrophic) Macular Degeneration Therapeutics, Global, Clinical Trials by Trial Status, 2020*
  • Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Global, by End Point Status, 2020*
  • Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2015-2019
  • Dry (Atrophic) Macular Degeneration Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2020*
  • Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Global, Key Sponsors, 2020*
  • Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Global, Top Companies by Phase, 2020*
  • Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2020*

List of Figures

List of Figures

  • Dry (Atrophic) Macular Degeneration Therapeutics, Global, Clinical Trials by Region (%), 2020*
  • Dry (Atrophic) Macular Degeneration Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2020*
  • Dry (Atrophic) Macular
目次
Product Code: GDHC6541CTIDB

GlobalData's clinical trial report, "Dry (Atrophic) Macular Degeneration Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Dry (Atrophic) Macular Degeneration Clinical trials scenario. This report provides top line data relating to the clinical trials on Dry (Atrophic) Macular Degeneration. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma - Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to Buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Report Guidance
  • GlobalData Clinical Trials Report Coverage
  • Clinical Trials by Region
  • Clinical Trials and Average Enrollment by Country
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
  • Top Five Countries Contributing to Clinical Trials in Europe
  • Top Countries Contributing to Clinical Trials in North America
  • Top Countries Contributing to Clinical Trials in Middle East and Africa
  • Top Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Dry (Atrophic) Macular Degeneration to Ophthalmology Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Dry (Atrophic) Macular Degeneration to Ophthalmology Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
  • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
  • Top Companies Participating in Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials
  • Prominent Drugs
  • Clinical Trial Profile Snapshots

Appendix

  • Abbreviations
  • Definitions
  • Research Methodology
  • Secondary Research
  • About GlobalData
  • Contact Us
  • Source
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.